Chimeric antigen receptor (CAR) T cells have emerged as a potent therapeutic approach for patients with certain haematological cancers, with multiple CAR T cell products currently approved by the FDA for those with relapsed and/or refractory B cell malignancies. However, in order to derive the desired level of effectiveness, patients need to successfully receive the CAR T cell infusion in a timely fashion. This process entails apheresis of the patient’s T cells, followed by CAR T cell manufacture. While awaiting infusion at an authorized treatment centre, patients may receive interim disease-directed therapy. Most patients will also receive a course of pre-CAR T cell lymphodepletion, which has emerged as an important factor in enabling durable responses. The time between apheresis and CAR T cell infusion is often not a simple journey, with each milestone being a critical step that can have important downstream consequences for the ability to receive the infusion and the strength of clinical responses. In this Review, we provide a summary of the many considerations for preparing patients with B cell non-Hodgkin lymphoma or acute lymphoblastic leukaemia for CAR T cell therapy, and outline current limitations and areas for future research.
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of certain forms of acute lymphoblastic leukaemia and B cell non-Hodgkin lymphoma; a deeper understanding of the considerations for patient preparation and management prior to infusion will probably further improve outcomes.
Bridging therapies and lymphodepleting regimens are both becoming important components of treatment with CAR T cell therapy; however, the available approaches often vary between patients, products and treating centres.
Bridging therapy can be comprised of a host of therapeutic options, including standard chemotherapy or, alternatively, immunotherapy and/or radiotherapy.
Patient-specific considerations, including the contexts of eligibility and timing of CAR T cell infusion, are imperative to determining the optimal treatment approach.
Here, we review the emerging data on patient selection, bridging therapies and lymphodepletion regimens administered before CAR T cell infusion, all of which are critical to improving clinical outcomes.
Your institute does not have access to this article
Open Access articles citing this article.
Journal of Hematology & Oncology Open Access 07 June 2022
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
Elsallab, M., Levine, B. L., Wayne, A. S. & Abou-El-Enein, M. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. https://doi.org/10.1016/S1470-2045(19)30729-6 (2020).
Food and Drug Administration (FDA). Center for Biologics Evaluation and Research. Approval Letter- ABECMA. https://www.fda.gov/media/147062/download (2021).
Food and Drug Administration (FDA). Center for Biologics Evaluation and Research. Approval Letter-Breyanzi https://www.fda.gov/media/145712/download (2021).
Food and Drug Administration (FDA). Center for Biologics Evaluation and Research. Approval Letter-Yescarta. https://www.fda.gov/media/108458/download (2017).
Food and Drug Administration (FDA). Center for Biologics Evaluation and Research. Approval Letter-Kymriah. https://www.fda.gov/media/106989/download (2017).
Food and Drug Administration (FDA). Center for Biologics Evaluation and Research. Approval Letter-Tecartus https://www.fda.gov/media/140415/download (2020).
Johnson, P. C. & Abramson, J. S. Patient selection for chimeric antigen receptor (CAR) T-cell therapy for aggressive B-cell non-Hodgkin lymphomas. Leuk. Lymphoma 61, 2561–2567 (2020).
Abou-el-Enein, M. et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. https://doi.org/10.1158/2643-3230.BCD-21-0084 (2021).
Allen, E. S. et al. Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion 57, 1133–1141 (2017).
Cahill, K. E., Leukam, M. J. & Riedell, P. A. Refining patient selection for CAR T-cell therapy in aggressive large B-cell lymphoma. Leuk. Lymphoma 61, 799–807 (2020).
Turtle, C. J. et al. Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. Blood 126, 184 (2015).
Hirayama, A. V. et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133, 1876–1887 (2019).
Perica, K. et al. Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia. Leukemia 35, 3268–3271 (2021).
Pinnix, C. C. et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv. 4, 2871–2883 (2020).
Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018).
Kadauke, S. et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J. Clin. Oncol. 39, 920–930 (2021).
Myers, R. M. et al. Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J. Clin. Oncol. 39, 3044–3055 (2021).
Martelli, M. et al. Diffuse large B-cell lymphoma. Crit. Rev. Oncol. Hematol. 87, 146–171 (2013).
Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800–1808 (2017).
Ramos, C. A., Heslop, H. E. & Brenner, M. K. CAR-T cell therapy for lymphoma. Annu. Rev. Med. 67, 165–183 (2016).
Sesques, P. et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center. Am. J. Hematol. 95, 1324–1333 (2020).
Jacobson, C. et al. Primary analysis of zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-hodgkin lymphoma (iNHL). Blood 136, 40–41 (2020).
Cappell, K. M. et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J. Clin. Oncol. 38, 3805–3815 (2020).
Nastoupil, L. J. et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium. J. Clin. Oncol. 38, 3119–3128 (2020).
Jacobson, C. A. et al. Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity. Blood 132, 92 (2018).
Bennani, N. N. et al. Experience with axicabtagene ciloleucel (Axi-cel) in patients with secondary CNS involvement: results from the US Lymphoma CAR T consortium. Blood 134, 763 (2019).
Frigault, M. J. et al. Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma. Blood 134, 860–866 (2019).
Neelapu, S. S. et al. Interim analysis of ZUMA-12: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell lymphoma (LBCL). Blood 136, 49 (2020).
Fesnak, A., Lin, C., Siegel, D. L. & Maus, M. V. CAR-T cell therapies from the transfusion medicine perspective. Transfus. Med. Rev. 30, 139–145 (2016).
Panch, S. R. et al. Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics. Mol. Ther. 27, 1275–1285 (2019).
Yakoub-Agha, I. et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica 105, 297–316 (2020).
Karschnia, P. et al. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood 133, 2212–2221 (2019).
Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715–727 (2021).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019).
Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690–700 (2021).
Topp, M. S. et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 195, 388–398 (2021).
Gardner, R. A. et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134, 2149–2158 (2019).
Whiteaker, J. R. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11, eaat6753 (2018).
Kawalekar, O. U. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. Immunity 44, 380–390 (2016).
Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T Ccells. Cancer Cell 28, 415–428 (2015).
Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019).
Riedell, P. A. et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Blood 134, 1599 (2019).
Gajra, A. et al. Neurological adverse events following CAR-T cell therapy: a real-world analysis of adult patients treated with axicabtagene ciloleucel or tisagenlecleucel. Blood 134, 1952 (2019).
Denlinger, N. et al. CAR T-cell therapy: clinical outcomes, patient selection and financial metrics with tisagenlecleucel and axicabtagene ciloleucel, a single center experience. Biol. Blood Marrow Transpl. 26, S266 (2020).
Abramson, J. S. et al. Pivotal safety and efficacy results from transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood 134, 241 (2019).
Brudno, J. N. et al. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma. Nat. Med. 26, 270–280 (2020).
Wagner, D. L. et al. Immunogenicity of CAR T cells in cancer therapy. Nat. Rev. Clin. Oncol. 18, 379–393 (2021).
Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145–161 (2021).
Pui, C.-H. et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J. Clin. Oncol. 33, 2938–2948 (2015).
Hunger, S. P. & Raetz, E. A. How I treat relapsed acute lymphoblastic leukemia in the pediatric population. Blood 136, 1803–1812 (2020).
Faderl, S., Jeha, S. & Kantarjian, H. M. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 98, 1337–1354 (2003).
Samra, B., Jabbour, E., Ravandi, F., Kantarjian, H. & Short, N. J. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J. Hematol. Oncol. 13, 70 (2020).
Rowe, J. M. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood 106, 3760–3767 (2005).
Kantarjian, H. et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 101, 2788–2801 (2004).
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
Shah, B. D. et al. Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). J. Clin. Oncol. 39, 7002 (2021).
Friberg, G. & Reese, D. Blinatumomab (Blincyto): lessons learned from the bispecific T-cell engager (BiTE) in acute lymphocytic leukemia (ALL). Ann. Oncol. 28, 2009–2012 (2017).
Orellana-Noia V. M., Portell C. A., Ballen K. In Chimeric Antigen Receptor T-cell Therapies for Cancer (eds Lee, D. W., Shah, N. N.) ch. 1 (Elsevier, 2020).
Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I Anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938–1950 (2020).
Pillai, V. et al. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Blood Adv. 3, 3539–3549 (2019).
Summers, C. et al. Hematopoietic cell transplantation after CD19 CAR T cell-induced ALL remission confers leukemia-free survival advantage. Transpl. Cell Ther. 28, 21–29 (2022).
Shah, N. N. et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J. Clin. Oncol. 39, 1650–1659 (2021).
McGuirk, J. et al. Building blocks for institutional preparation of CTL019 delivery. Cytotherapy 19, 1015–1024 (2017).
Pan, J. et al. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Leukemia 33, 2854–2866 (2019).
Dai, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J. Hematol. Oncol. 13, 30 (2020).
Liu, S. et al. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Am. J. Hematol. 96, 671–679 (2021).
Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396, 839–852 (2020).
Hernandez, I., Prasad, V. & Gellad, W. F. Total costs of chimeric antigen receptor T-cell immunotherapy. JAMA Oncol. 4, 994 (2018).
Kansagra, A., Farnia, S. & Majhail, N. Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities. Am. Soc. Clin. Oncol. Educ. B https://doi.org/10.1200/EDBK_279151 (2020).
Nieto, M. J., Li, Z., Rehman, H. & Saif, M. W. Lower 24-month relative survival among black patients with non-Hodgkin’s lymphoma: an analysis of the SEER data 1997-2015. J. Clin. Haematol. 2, 5–13 (2021).
Sasaki, K. et al. Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER). Am. J. Hematol. 96, 650–658 (2021).
Raca, G. et al. Increased incidence of IKZF1 deletions and IGH-CRLF2 translocations in B-ALL of Hispanic/Latino children — a novel health disparity. Leukemia 35, 2399–2402 (2021).
Nastoupil, L. J. et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood 132, 91 (2018).
Jain, M. D. et al. Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood 134 (Suppl. 1), 245 (2019).
Chabner, B. A. & Roberts, T. G. Chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65–72 (2005).
Blanco, B., Domínguez-Alonso, C. & Alvarez-Vallina, L. Bispecific immunomodulatory antibodies for cancer immunotherapy. Clin. Cancer Res. 27, 5457–5464 (2021).
Scott, A. M., Allison, J. P. & Wolchok, J. D. Monoclonal antibodies in cancer therapy. Cancer Immun. 12, 14 (2012).
Schaue, D. & McBride, W. H. Opportunities and challenges of radiotherapy for treating cancer. Nat. Rev. Clin. Oncol. 12, 527–540 (2015).
Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).
Andreadis, C. et al. Correlation of bridging and lymphodepleting chemotherapy with clinical outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma treated with tisagenlecleucel. Blood 134, 2883 (2019).
Kansagra, A. J. et al. Clinical utilization of chimeric antigen receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) — an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplant. Bone Marrow Transpl. 54, 1868–1880 (2019).
Dwivedy Nasta, S. et al. A characterization of bridging therapies leading up to commercial CAR T-cell therapy. Blood 134, 4108 (2019).
Paillassa, J. et al. Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse/refractory diffuse large B- cell lymphoma in real world experience. Blood 134, 2886 (2019).
Hutchings, M. et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol. 39, 1959–1970 (2021).
Cao, Y. et al. Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell non-Hodgkin lymphoma. Front. Oncol. 9, 767 (2019).
Schuster, S. J. et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood 134, 6 (2019).
Liebers, N. et al. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 5, 2707–2716 (2021).
Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018).
Thapa, B. et al. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 4, 3850–3852 (2020).
Oliai, C. & de Vos, S. Case report: sustained remission achieved from anti-CD19 CAR T cell therapy despite prior treatment with anti-CD19 antibody tafasitamab (MOR208) in a patient with relapsed and refractory diffuse large B-cell lymphoma. Blood 134, 5360 (2019).
Horvei, P. et al. Targeting of CD19 by tafasitamab does not impair CD19 directed chimeric antigen receptor T cell activity in vitro. Biol. Blood Marrow Transpl. 26, S223–S224 (2020).
Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
Wright, C. M. et al. Bridging radiation therapy before commercial chimeric antigen receptor T-cell therapy for relapsed or refractory aggressive B-cell lymphoma. Int. J. Radiat. Oncol. 108, 178–178 (2020).
Gupta, S. et al. High vs. low-intensity bridging chemotherapy in children with acute lymphoblastic leukemia awaiting chimeric antigen receptor T-cell therapy: a population-based study from Ontario, Canada. Blood 132, 1410 (2018).
Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398, 491–502 (2021).
Shahid, S. et al. Impact of bridging chemotherapy on clinical outcomes of CD19-specific CAR T cell therapy in children/young adults with relapsed/refractory B cell acute lymphoblastic leukemia. Transpl. Cell Ther. 28, 72.e1–72.e8 (2021).
Mahadeo, K. M. et al. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat. Rev. Clin. Oncol. 16, 45–63 (2019).
Weber, E. W. et al. Pharmacologic control of CAR-T cell function using dasatinib. Blood Adv. 3, 711–717 (2019).
Mestermann, K. et al. The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Sci. Transl. Med. 11, eaau5907 (2019).
Brown, P.A. & et al. A randomized phase 3 trial of blinatumomab vs. chemotherapy as post-reinduction therapy in high and intermediate risk (HR/IR) first relapse of B-acute lymphoblastic leukemia (B-ALL) in children and adolescents/young adults (AYAs) demonstrates superior efficacy and tolerability of blinatumomab: a report from Children’s Oncology Group Study AALL1331. Blood 134 (Suppl. 2), LBA-1 (2019).
Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375, 740–753 (2016).
Libert, D. et al. Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy. Leukemia 34, 3064–3069 (2020).
Myers, R. M. et al. Blinatumomab non-response and high disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. J. Clin. Oncol. https://doi.org/10.1200/JCO.21.01405 (2021).
Jacoby, E. et al. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am. J. Hematol. 93, 1485–1492 (2018).
Gaudichon, J. et al. Mechanisms of extramedullary relapse in acute lymphoblastic leukemia: reconciling biological concepts and clinical issues. Blood Rev. 36, 40–56 (2019).
Marquez, C. P. et al. Use of cardiac radiation therapy as bridging therapy to CAR-T for relapsed pediatric B-cell acute lymphoblastic leukemia. Pediatr. Blood Cancer https://doi.org/10.1002/pbc.28870 (2021).
Denton, C. C. et al. Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv. 4, 2158–2162 (2020).
Grigor, E. J. M. et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus. Med. Rev. 33, 98–110 (2019).
Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J. Clin. Oncol. 35, 1803–1813 (2017).
Wrzesinski, C. et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J. Immunother. 33, 1–7 (2010).
Ninomiya, S. et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood 125, 3905–3916 (2015).
Emadi, A., Jones, R. J. & Brodsky, R. A. Cyclophosphamide and cancer: golden anniversary. Nat. Rev. Clin. Oncol. 6, 638–647 (2009).
Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood 137, 323–335 (2021).
Turtle, C. J. et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells. Sci. Transl. Med. 8, 355ra116 (2016).
Gust, J. et al. Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells. Cancer Discov. 7, 1404–1419 (2017).
Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130, 2295–2306 (2017).
Hill, J. A. et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131, 121–130 (2018).
Kochenderfer, J. N. et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33, 540–549 (2015).
Gardner, R. A. et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood 129, 3322–3331 (2017).
Turtle, C. J. et al. CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016).
Sarkar, R. R., Gloude, N. J., Schiff, D. & Murphy, J. D. Cost-effectiveness of chimeric antigen receptor T-cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. JNCI 111, 719–726 (2019).
Tsao, L.-C., Force, J. & Hartman, Z. C. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 81, 4641–4651 (2021).
Wang, C. et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2, 846–856 (2014).
Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327–344 (2021).
Sutherland, M. S. K. et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J. Biol. Chem. 281, 10540–10547 (2006).
Fuh, F. K. et al. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells. Br. J. Pharmacol. 174, 628–640 (2017).
Takeshita, A. et al. CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells. Leukemia 23, 1329–1336 (2009).
Jain, N. et al. Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 4, 449–457 (2020).
Löffler, A. et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95, 2098–2103 (2000).
Sun, L. L. et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aaa4802 (2015).
Bröske, A.-M. E. et al. CD20-TCB, a novel T-cell-engaging bispecific antibody, induces T-cell-mediated killing in relapsed or refractory non-hodgkin lymphoma: biomarker results from a phase I dose-escalation trial. Blood 134, 5319 (2019).
Burger, J. A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic Leukemia. N. Engl. J. Med. 373, 2425–2437 (2015).
Byrd, J. C. et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 323–332 (2016).
Konig, H. et al. Effects of dasatinib on src kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 68, 9624–9633 (2008).
LeBlanc, R. et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103, 1787–1790 (2004).
Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9, 338–350 (2009).
Crook, T. R., Souhami, R. L. & McLean, A. E. Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells. Cancer Res. 46, 5029–5034 (1986).
Cai, J. et al. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 68, 2349–2357 (2008).
Keating, M. et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 74, 19–25 (1989).
Singh, A. & Xu, Y.-J. The cell killing mechanisms of hydroxyurea. Genes 7, 99 (2016).
Avramis, V. I. Asparaginases: a successful class of drugs against leukemias and lymphomas. J. Pediatr. Hematol. Oncol. 33, 573–579 (2011).
Schmiegelow, K., Nielsen, S. N., Frandsen, T. L. & Nersting, J. Mercaptopurine/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 36, 503–517 (2014).
Jordan, M. A., Himes, R. H. & Wilson, L. Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer Res. 45, 2741–2747 (1985).
Sionov, R.V., Spokoini, R., Kfir-Erenfeld, S., Cohen, O. & Yefenof, E. Mechanisms regulating the susceptibility of hematopoietic malignancies to glucocorticoid-induced apoptosis. Adv. Cancer Res. 101, 127–248 (2008).
Huang, R.-X. & Zhou, P.-K. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal. Transduct. Target. Ther. 5, 60 (2020).
This work was supported in part by the Intramural Research Program, Center of Cancer Research, US National Cancer Institute, National Institutes of Health (ZIA BC 011823, N.N.S.). The authors would like to thank Professor Richard Grose (Barts Cancer Institute, Queen Mary University of London, UK) for his critical review of the figures. The content of this publication does not necessarily reflect the views of policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
S.L.M. has acted as a consultant and/or adviser of and has received research funding from Novartis and Wugen. L.J.N. has received honoraria from ADC Therapeutics, Bayer, BMS/Celgene, Epizyme, Genentech, Gilead/Kite, Janssen, Morphosys, Novartis, Pfizer, TG Therapeutics; and has received research funding from BMS/Celgene, Caribou Biosciences, Epizyme, Genentech, Gilead/Kite, IGM Biosciences, Janssen, Novartis, Pfizer, TG Therapeutics. C.A.R. has acted as an adviser of Novartis and has received research funding from Athenex and Tessa Therapeutics. R.J.B. has licensed intellectual property to and collects royalties from BMS, Caribou and Sanofi; has received research funding from BMS; has acted as a consultant of Atara Biotherapeutics, BMS and Gracell Biotechnologies. C.S.S. has acted as a consultant of Celgene/BMS, Gamida Cell, Genmab, GSK, Juno Therapeutics, Karyopharm Therapeutics, Kite/a Gilead Company, Novartis, Precision Biosciences, Sanofi-Genzyme, and Spectrum Pharmaceuticals and has received research funding from Celgene/BMS, Bristol-Myers Squibb, Juno Therapeutics, Precision Biosciences and Sanofi-Genzyme. L. A., S.K.S., N.N.S. and M.A. declare no competing interests.
Nature Reviews Clinical Oncology thanks the anonymous reviewers for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Amini, L., Silbert, S.K., Maude, S.L. et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol 19, 342–355 (2022). https://doi.org/10.1038/s41571-022-00607-3
Journal of Hematology & Oncology (2022)